[
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=ef84719e665e6d8b2e5bbdb71ffafc80a66adcb2cd05cb3966d8b852b54ef1c8",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746031140,
      "headline": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "id": 134191778,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=ef84719e665e6d8b2e5bbdb71ffafc80a66adcb2cd05cb3966d8b852b54ef1c8"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Insider Buying Fund Q1 2025 Commentary",
    "summary": "The Davenport Insider Buying Fund (DBUYX) generated a -5.96% total return in the first quarter of 2025. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=f52f52127c7c16e9540f88b16ba300fdfda063ecef2823ccdab8e6bcd061f6ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746013500,
      "headline": "The Davenport Insider Buying Fund Q1 2025 Commentary",
      "id": 134146439,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1322205526/image_1322205526.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Davenport Insider Buying Fund (DBUYX) generated a -5.96% total return in the first quarter of 2025. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=f52f52127c7c16e9540f88b16ba300fdfda063ecef2823ccdab8e6bcd061f6ca"
    }
  },
  {
    "ts": null,
    "headline": "The Davenport Value & Income Fund Q1 2025 Commentary",
    "summary": "The Davenport Value & Income Fund generated a 3.83% total return in Q1 2025, outperforming the Russell 1000 ValueÂ® Index. Click here to read the full commentary.",
    "url": "https://finnhub.io/api/news?id=96d3c7497f3ba63eec08c4af14f9777376153d1dbd6279bd521bdef95107b09d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746009000,
      "headline": "The Davenport Value & Income Fund Q1 2025 Commentary",
      "id": 134145461,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1598043982/image_1598043982.jpg?io=getty-c-w1536",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "The Davenport Value & Income Fund generated a 3.83% total return in Q1 2025, outperforming the Russell 1000 ValueÂ® Index. Click here to read the full commentary. ",
      "url": "https://finnhub.io/api/news?id=96d3c7497f3ba63eec08c4af14f9777376153d1dbd6279bd521bdef95107b09d"
    }
  },
  {
    "ts": null,
    "headline": "UK's MHRA Authorises Cancer Treatment Variation With An Administration Time Of 3-5 Minutes",
    "summary": "UK'S MHRA: * UK'S MHRA: AUTHORISES CANCER TREATMENT VARIATION WITH ANADMINISTRATION TIME OF 3–5 MINUTES - WEBSITE * UK'S MHRA: APPROVED NEW UNDER-THE-SKIN INJECTION...",
    "url": "https://finnhub.io/api/news?id=fd0f3459ef6a2ca4c452ab34aab2d0dc21215cb9b4a56981099ba8bc67373868",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1746008677,
      "headline": "UK's MHRA Authorises Cancer Treatment Variation With An Administration Time Of 3-5 Minutes",
      "id": 134145298,
      "image": "",
      "related": "BMY",
      "source": "Finnhub",
      "summary": "UK'S MHRA: * UK'S MHRA: AUTHORISES CANCER TREATMENT VARIATION WITH ANADMINISTRATION TIME OF 3–5 MINUTES - WEBSITE * UK'S MHRA: APPROVED NEW UNDER-THE-SKIN INJECTION...",
      "url": "https://finnhub.io/api/news?id=fd0f3459ef6a2ca4c452ab34aab2d0dc21215cb9b4a56981099ba8bc67373868"
    }
  },
  {
    "ts": null,
    "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires?",
    "summary": "We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every day and billionaire investors. A CNBC report […]",
    "url": "https://finnhub.io/api/news?id=bfabd13fee161171866dc9d83a443dd671aa93ed870cac4e8b56aed8be2c798c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1745972394,
      "headline": "Is Bristol-Myers Squibb Company (BMY) the Best Long-Term Dividend Stock to Buy According to Billionaires?",
      "id": 134141817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "We recently published a list of the 10 Best Long-Term Dividend Stocks to Buy According to Billionaires. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best long-term dividend stocks. Dividend stocks are increasingly popular with both every day and billionaire investors. A CNBC report […]",
      "url": "https://finnhub.io/api/news?id=bfabd13fee161171866dc9d83a443dd671aa93ed870cac4e8b56aed8be2c798c"
    }
  }
]